Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | CaaMTech Solves Crystal Structure of Psychedelic Drug PsilacetinPsilacetin (4-AcO-DMT) primed to replace synthetic psilocybin and magic mushrooms in future psychedelic research.
By: CaaMTech "Psilacetin is much more easily prepared than psilocybin," "This is the first time that the scientific community has been able to look directly at this molecule," said Dr. Andrew Chadeayne, president of CaaMTech. "This is really the first scientific proof that psilacetin exists. While previous work provided clues about psilacetin, now we know the structure definitively." Fundamental physical characterization is required to understand and develop any molecule. For psilacetin, this information is especially important for realizing its potential value as a pharmaceutical. Several companies including UK startup COMPASS Pathways are currently developing synthetic psilocybin as a commercial drug product. Psilacetin provides the same benefits as psilocybin and is more potent than psilocybin at only 1/100th of the cost. "Getting the chance to work on the structure of psilacetin was a great opportunity," CaaMTech researchers used single-crystal X-ray crystallography to solve psilacetin's structure on a diffractometer funded through a grant from the National Science Foundation. According the American Chemical Society, X-ray crystallography "is widely considered to be the gold standard for establishing the structures of crystalline solids." Max von Laue, Walter Friedrich, and Paul Knipping discovered X-ray diffraction by crystals in April 1912, for which von Laue was awarded the 1914 Nobel Prize in Physics. Since then, twenty-eight Nobel Prizes have been awarded for discoveries in crystallography, more than any other scientific field. Read the publication at Psychedelic Science Review: https://psychedelicreview.com/ --- About CaaMTech CaaMTech is pioneering next-generation psychedelic drugs for the 21st century. CaaMTech was founded in 2018 by chemist, inventor and intellectual property expert, Dr. Andrew Chadeayne. --- Contacts Media: CaaMTech Media Team – press@caam.tech Science and Research: Dr. Andrew Chadeayne – andrew@caam.tech Investors and Business: Pat Donohue – pat@caam.tech Press Release Assets: https://caam.tech/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|